Drug intelligence / Profile preview

Oftalipid

Development stage: Unknown
Lead developer: Visum Pharm
Modality: Small Molecules
Administration: Ophthalmic

Overview

Oftalipid is an ophthalmic lipid emulsion developed by Visum Pharm for the treatment of dry eye syndrome (keratoconjunctivitis sicca). The product is specifically formulated to address evaporative dry eye by replenishing and stabilizing the lipid layer of the tear film, which reduces the rate of aqueous tear evaporation. Its composition includes phospholipids (soy lecithin) and medium-chain triglycerides that integrate into the tear film's lipid phase, alongside Vitamin A (retinyl palmitate) to promote corneal epithelial health and Vitamin E (alpha-tocopherol) for its antioxidant properties. Oftalipid is used to provide long-lasting lubrication and relief from symptoms such as ocular dryness, irritation, and the sensation of a foreign body.

Brand names: Oftalipid
Other names: OFTAlipid

Beyond the preview

Go deeper on Oftalipid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oftalipid.

Explore the full profile